Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pancreatic cancer
Stage/Subtype:  stage III pancreatic cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 101 for your search:
Start Over
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: 90914721, NCI-2016-00348, CDM00047339, E7059, NCT01774019
Surgery With or Without Intraperitoneal Drainage in Improving Complication Rate in Patients With Pancreatic Disease
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: H-28324, NCI-2012-01881, NCT01441492
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 19211, NCI-2012-00026, NCT01506973
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740
A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FGCL-3019-069, NCI-2015-01207, NCT02210559
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Tosedostat and Capecitabine in Treating Patients with Pancreatic Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201503074, NCI-2015-00425, NCT02352831
WEE1 Inhibitor AZD1775, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2013.094, NCI-2014-01214, HUM00079048, NCT01916551, NCT02037230
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FF-10502-01, NCI-2016-00184, NCT02661542
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20150195, NCI-2016-01042, MASTERKEY, NCT02713529
LMB-100 with or without Nab-Paclitaxel in Treating Patients with Mesothelin Positive Solid Tumors or Recurrent, Metastatic, and/or Locally Advanced Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0128, NCI-2016-00945, 355879, P152592, NCT02810418
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMCS110Z2102, NCI-2016-01142, 2016-000210-29, NCT02807844
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMT212X2106, NCI-2016-01156, 2015-005019-34, NCT02703571
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CBLZ945X2101, NCI-2016-01505, 2015-005806-12, NCT02829723
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-15, NCI-2016-01997, NCT02559674
A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 24360-207 / ECHO-207, NCI-2017-00578, NCT03085914
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IT-01, NCI-2017-01040, NCT03058289
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-9GW, NCI-2017-01330, 2017-000367-33, NCT03098550
Start Over